These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17496161)

  • 1. Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1.
    Zhang Z; Liao B; Xu M; Jin Y
    FASEB J; 2007 Oct; 21(12):3042-51. PubMed ID: 17496161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dnmt3b, de novo DNA methyltransferase, interacts with SUMO-1 and Ubc9 through its N-terminal region and is subject to modification by SUMO-1.
    Kang ES; Park CW; Chung JH
    Biochem Biophys Res Commun; 2001 Dec; 289(4):862-8. PubMed ID: 11735126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extended consensus motif enhances the specificity of substrate modification by SUMO.
    Yang SH; Galanis A; Witty J; Sharrocks AD
    EMBO J; 2006 Nov; 25(21):5083-93. PubMed ID: 17036045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
    Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
    Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BS69 undergoes SUMO modification and plays an inhibitory role in muscle and neuronal differentiation.
    Yu B; Shao Y; Zhang C; Chen Y; Zhong Q; Zhang J; Yang H; Zhang W; Wan J
    Exp Cell Res; 2009 Dec; 315(20):3543-53. PubMed ID: 19766626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUMO Ubc9 enzyme as a viral target.
    Varadaraj A; Mattoscio D; Chiocca S
    IUBMB Life; 2014 Jan; 66(1):27-33. PubMed ID: 24395713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
    Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
    Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of Smad4 transcriptional activity by SUMO modification.
    Long J; Wang G; He D; Liu F
    Biochem J; 2004 Apr; 379(Pt 1):23-9. PubMed ID: 14750902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2.
    Zhang H; Smolen GA; Palmer R; Christoforou A; van den Heuvel S; Haber DA
    Nat Genet; 2004 May; 36(5):507-11. PubMed ID: 15107848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs).
    Wu YC; Roark AA; Bian XL; Wilson VG
    Virology; 2008 Sep; 378(2):329-38. PubMed ID: 18619639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reprogramming factor nuclear receptor subfamily 5, group A, member 2 cannot replace octamer-binding transcription factor 4 function in the self-renewal of embryonic stem cells.
    Choi KW; Oh HR; Lee J; Lim B; Han YM; Oh J; Kim J
    FEBS J; 2014 Feb; 281(4):1029-45. PubMed ID: 24341592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation.
    Jakobs A; Koehnke J; Himstedt F; Funk M; Korn B; Gaestel M; Niedenthal R
    Nat Methods; 2007 Mar; 4(3):245-50. PubMed ID: 17277783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
    Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
    J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation.
    Ji Z; Degerny C; Vintonenko N; Deheuninck J; Foveau B; Leroy C; Coll J; Tulasne D; Baert JL; Fafeur V
    Oncogene; 2007 Jan; 26(3):395-406. PubMed ID: 16862185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes.
    Bossis G; Melchior F
    Mol Cell; 2006 Feb; 21(3):349-57. PubMed ID: 16455490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SUMO modification regulates the transcriptional activity of FLASH.
    Alm-Kristiansen AH; Norman IL; Matre V; Gabrielsen OS
    Biochem Biophys Res Commun; 2009 Sep; 387(3):494-9. PubMed ID: 19615980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent conjugation of the equine infectious anemia virus Gag with SUMO.
    Wang J; Wen S; Zhao R; Qi J; Liu Z; Li W; An J; Wood C; Wang Y
    Biochem Biophys Res Commun; 2017 May; 486(3):712-719. PubMed ID: 28342872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription.
    Ling Y; Sankpal UT; Robertson AK; McNally JG; Karpova T; Robertson KD
    Nucleic Acids Res; 2004; 32(2):598-610. PubMed ID: 14752048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubc9-mediated sumoylation leads to transcriptional repression of IRF-1.
    Kim EJ; Park JS; Um SJ
    Biochem Biophys Res Commun; 2008 Dec; 377(3):952-6. PubMed ID: 18955028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SUMO conjugating enzyme Ubc9 is required for inducing and maintaining stem cell pluripotency.
    Tahmasebi S; Ghorbani M; Savage P; Gocevski G; Yang XJ
    Stem Cells; 2014 Apr; 32(4):1012-20. PubMed ID: 24706591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.